CytomX Therapeutics Files 8-K on Financials and Operations
Ticker: CTMX · Form: 8-K · Filed: May 12, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
CytomX filed an 8-K on May 12th covering financials and other events.
AI Summary
CytomX Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This 8-K filing provides investors with crucial updates on CytomX Therapeutics' financial health and operational developments, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on financial condition and operations, with no immediate indication of significant new risks.
Key Numbers
- 001-37587 — Commission File Number (Identifies the company's SEC filing history.)
- 27-3521219 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Registrant
- May 12, 2025 (date) — Date of earliest event reported
- South San Francisco, California (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates reporting on 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.
Are there any material 'Other Events' being disclosed?
The filing states 'Other Events' are being reported, but the specific nature of these events is not detailed in the provided text.
What is the primary business of CytomX Therapeutics, Inc. based on the SIC code?
The Standard Industrial Classification (SIC) code provided is 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
When was the earliest event reported in this filing?
The earliest event reported is dated May 12, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 151 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding CytomX Therapeutics, Inc. (CTMX).